A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis

Non-alcoholic steatohepatitis (NASH) is major health burden lacking effective pharmacological therapies. Clinical trials enrol patients with histologically-defined NAFLD (non-alcoholic fatty liver disease) activity score (NAS) ≥ 4 and Kleiner-Brunt fibrosis stage (F) ≥ 2; however, screen failure rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dennis, Andrea, Mouchti, Sofia, Kelly, Matt, Fallowfield, Jonathan A., Hirschfield, Gideon, Pavlides, Michael, Banerjee, Rajarshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499258/
https://www.ncbi.nlm.nih.gov/pubmed/32943694
http://dx.doi.org/10.1038/s41598-020-71995-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499258/
https://www.ncbi.nlm.nih.gov/pubmed/32943694
http://dx.doi.org/10.1038/s41598-020-71995-8

Ejemplares similares